SCHEMBL5745127

SCHEMBL5745127

CC(C)(C)[Si](C)(C)OCc1cc(Cl)nc(NC(=O)O)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP14 P54578 1/20 0.34
S1PR2 O95136 3/20 0.34
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
TACR1 P25103 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
KMT2A Q03164 3/20 0.32
KDM4E B2RXH2 2/20 0.32
BACE1 P56817 1/20 0.32
MEN1 O00255 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
AGPAT2 O15120 2/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102172 0.88 SCN9A (0.39) ALDH1A1
SCHEMBL5743568 0.85 KMT2A (0.34) USP14RAB9ANPC1TACR1ALDH1A1
SCHEMBL3407078 0.80 USP14 (0.32) USP14TACR1
SCHEMBL20642394 0.78 USP14 (0.32) USP14
SCHEMBL22631358 0.77 S1PR2 (0.39) S1PR2RAB9ANPC1ALDH1A1HPGD
SCHEMBL5742388 0.76 MAPKAPK2 (0.39)
SCHEMBL21158927 0.75 CA12 (0.30)
SCHEMBL22689537 0.75 BACE1 (0.35) S1PR2TACR1ALDH1A1HPGDKMT2A
SCHEMBL3145992 0.75 GRM5 (0.30)
SCHEMBL19306519 0.75 KLK7 (0.41) RAB9ANPC1HPGDKMT2ABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1404672-B1 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2006-01-18 EP disclosed
US-6875767-B2 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors MERCK & CO., INC. (US) 2005-04-05 US disclosed
EP-1404672-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2004-04-07 EP disclosed
US-20030100567-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2003-05-29 US disclosed
WO-2003000687-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100567-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 USP14 3175/4885S1PR2 1305/4885RAB9A 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.